Other Transaction Agreement 140D042690027
Award Date 7/31/26
Potential Completion Date 7/30/31
Potential Value $20M
Funding Federal Agency
Contracting Federal Agency
Ultimate Awardee
Not listed NAICS Category
Not listed Set-Aside Type
Not listed Federal Contract Vehicle
- Not listed
Extent Competed
Competed
Major Defense Program
Not listed Pricing Type
Other
Place of Performance
Woodland Hills, CA 91367, USA
Solicitation Procedures
Program Solicitation
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The National Institutes of Health awarded an Other Transaction Agreement to Syracuse University for $2,256,884 on February 20, 2026, to develop lego-like assembly of perfusable extracellular matrix cubes to generate tissue-agnostic, suturable, organ-sized, viable and functional grafts. The agreement sits outside the Federal Acquisition Regulation as an OTA. Work will be performed in Syracuse, New York, with an ultimate completion date of February 19, 2029. This represents a research and...
- Acrocyte Therapeutics Inc. has been awarded an Other Transaction Agreement valued at $4.37M by the National Institutes of Health (NIH) to develop rapid and reliable autologous cell screening and expansion technologies for organoid therapy. The contract, awarded on March 19, 2026, with an ultimate completion date of March 18, 2029, will be performed at the company's facility in Fremont, California. This effort supports NIH's broader mission to advance regenerative medicine and cell-based...
- The Defense Health Agency awarded an Other Transaction Order to Medical Technology Enterprise Consortium for the Armed Forces Institute for Regenerative Medicine research project, with a ceiling value of $57.8 million and an award date of September 15, 2023. The order funds research into regenerative medicine solutions for military personnel healthcare applications. Place of performance is Summerville, SC. The ultimate completion date is December 23, 2028. MTEC, a nonprofit medical technology...
- The National Institutes of Health awarded an Other Transaction Agreement to Beckman Research Institute of the City of Hope valued at $23,669,424 on May 20, 2025, for ADAPT-5205-P: immunotherapy biomarker collection for metastatic non-small cell lung cancer to inform adaptive personalized models targeting resistance. The agreement sits outside the Federal Acquisition Regulation as an OTA. Performance extends through May 19, 2031, with work conducted in Irwindale, California. The effort supports...
- The National Institutes of Health awarded a $17.87 million definitive contract to Advanced Regenerative Manufacturing Institute Inc. (Armi) for independent validation and verification services supporting the ARPA-H Resilient Extended Automatic Cell Therapies (REACT) program on June 1, 2026. The originating solicitation, posted November 24, 2025 with proposals due January 5, 2026, describes IV&V services critical to standardization and reproducibility of engineered cell lines for two...
- The National Institutes of Health (NIH) has awarded an Other Transaction Agreement (OTA) valued at $48M to Kernal Biologics, Inc., a Cambridge, Massachusetts-based biotechnology firm, for selective mRNA-lipid nanoparticle (LNP) engineering aimed at cost-effective in situ CAR T-cell programming. The contract, awarded on September 16, 2025, extends through September 15, 2031, and represents a non-traditional acquisition vehicle that allows the NIH greater flexibility in structuring terms and...
- The National Institutes of Health has awarded an Other Transaction Agreement to Immunovec, Inc. (UEI: Y3XYSZYYJRN4) valued at approximately $40.7 million for the development of specialized, polymer-based, efficient, cell type-targeted injections for innovative cures. The contract was awarded on September 22, 2025, with an ultimate completion date of September 21, 2031, and will be performed in Malibu, California. This contract type reflects NIH's use of flexible authorities to support innovative...
- The National Institutes of Health (NIH) awarded the University of Southern California an Other Transaction Agreement valued at $6.84M on February 27, 2026, for "Evidence-Driven Manufacturing to Expand Pediatric Cell Therapy Access in Rare Diseases," with completion targeted for March 31, 2028. This civilian research contract will be performed in Los Angeles, California, and represents NIH's investment in expanding access to advanced cell therapy treatments for pediatric patients with...
- The National Institutes of Health awarded an Other Transaction Agreement to Global Life Sciences Solutions USA LLC for $40,130,860 to develop CRISPR delivery and manufacturing innovation for minimal-cost cancer and HIV therapies via in vivo immune engineering, with an award date of September 25, 2025. The agreement runs through September 24, 2031 and is performed in Marlborough, Massachusetts. As an OTA, this agreement operates outside the Federal Acquisition Regulation and represents a...
- The National Institutes of Health awarded a $600,000 definitive contract to Halcyon Biomedical Inc. on March 2, 2026, under a total small business set-aside for a point-of-care system for cell therapy manufacturing and delivery. The award stems from ARPA-H's FY2024 SBIR/STTR topic areas, issued as a pre-solicitation notice in May 2024 with proposals due July 2, 2024. The contract is firm fixed price with an ultimate completion date of September 1, 2027. Place of performance is Friendswood, TX.